G Bradley Cole

CIK 1337798 · General Manager - Diagnostics · last filed 2026-07-31

G Bradley Cole is a General Manager - Diagnostics who has filed 156 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for KNSA, was dated Jul 31, 2026. Across all open-market trades the lifetime net is −$33.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions. 6 SEC filings were submitted jointly with EXACT SCIENCES CORP. 2 Form 144 notices of planned sales are also on file; the latest, for KNSA on Jul 29, 2026, lists the filer as a director.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.79M
Companies
4
Total Filings
156
Lifetime Open-Market Net
-$33.74M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

GHDX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
301 PENOBSCOT DRIVE
REDWOOD CITY, CA 94063
Related Filers
EXACT SCIENCES CORP — 6 joint filings, latest 2020-02-21
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KNSA Director 7,172 $94.11 $675.0K -$299.1K 9 2026-07-31
CSTL Director 32,976 $33.79 $1.11M -$210.7K 12 2026-06-01
EXACT SCIENCES CORP (EXAS) Delisted General Manager - Diagnostics 22,528 $104.91 $2.36M -$5.89M 4 2020-02-21
GENOMIC HEALTH INC (GHDX) Delisted CFO 84,342 — — -$27.34M 128 2019-10-09

Holdings By Holder

Who holds the shares on record: the insider directly, and each trust, LLC, partnership or family member reported as an indirect holder on the latest Form 4 that lists them. Holder names come from the filing's footnotes. Rows under No longer reported appeared on earlier filings but not the latest one, usually because the holder was emptied or folded into another; they are not counted in the total.
Symbol Holder Shares Share of Total Reported
EXAS Direct 10,194 45.3% 2020-02-21
Held by Cole Family Trust 12,334 54.7% 2020-01-17
Total 22,528
No longer reported
By Cole Family Trust 12,334 — last 2019-11-25
GHDX Direct 45,372 53.8% 2018-11-15
Held by the Cole Family Trust 38,970 46.2% 2019-10-09
Total 84,342
No longer reported
Held by daughter 1,000 — last 2009-02-18
By daughter 1,000 — last 2009-01-07

Recent Filings

156 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2026-07-31 KNSA Mixed −8,173 -$299.1K EDGAR
2026-07-29 KNSA Notice (144)
Director · Planned Jul 29, 2026
Sold: Form 4 filed Jul 31, 2026
−3,673 -$299.1K EDGAR
2026-06-02 KNSA Mixed +2,799 $0 EDGAR
2026-06-01 CSTL Grant (A) — $0 EDGAR
2026-05-27 CSTL Exer (M) +13,667 $0 EDGAR
2026-03-09 CSTL Mixed −2,655 -$194.7K EDGAR
2026-03-05 CSTL Notice (144)
Director · Seller: Gordon B. Cole · Planned Mar 5, 2026
Sold: Form 4 filed Mar 9, 2026
−7,403 -$210.7K EDGAR
2025-06-05 KNSA Mixed +3,173 $0 EDGAR
2025-05-23 CSTL Mixed +8,673 $0 EDGAR
2024-06-07 KNSA Mixed +4,373 $0 EDGAR
Showing 1–10 of 156
Page 1 of 16
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).